n (%) | Week 12 | Week 52 | ||
---|---|---|---|---|
Placebo + NBBM (n = 158) | CZP 200 mg Q2W + NBBM (n = 159) | Placebo + NBBM (n = 158) | CZP 200 mg Q2W + NBBM (n = 159) | |
ASDAS-MI | 10 (6.3) | 56 (35.2) | 11 (7.0) | 75 (47.2) |
ASAS40 | 18 (11.4) | 76 (47.8) | 25 (15.8) | 90 (56.6) |
BASDAI50 | 23 (14.6) | 68 (42.8) | 19 (12.0) | 88 (55.3) |
ASDAS-ID | 2 (1.3) | 26 (16.4) | 6 (3.8) | 44 (27.7) |